Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor DLBCL (Other Subtype)
NCT06891157Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Aug 2024; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06891157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891157.